Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – PHASE III CLINICAL STUDY OF JS001SC FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS NSCLC MET PRIMARY ENDPOINTS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 24 November 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that a multi-center, open-label, randomized controlled phase III clinical study to compare toripalimab injection (subcutaneous injection) (code: JS001sc) and toripalimab injection (trade name: TUOYI® (拓益®), code: JS001) in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer ("**NSCLC**") (the "**JS001sc-002-III-NSCLC Study**", NCT06505837) has met the primary endpoints. The Company plans to submit the new drug application of this product to the regulatory authorities in the near future.

ABOUT JS001sc

JS001sc is a subcutaneous injection formulation developed by the Company on the basis of marketed product toripalimab injection. It is the first domestic anti-PD-1 monoclonal antibody subcutaneous formulation to enter phase III clinical study, and is expected to bring convenient administration to patients. As at the date of this announcement, a multi-center, open-label, randomized controlled phase III clinical study to compare JS001sc and toripalimab injection in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous NSCLC (the JS001sc-002-III-NSCLC Study) has met the primary endpoints.

ABOUT JS001sc-002-III-NSCLC STUDY

According to data released by GLOBOCAN 2022, in 2022, there were 1.06 million new lung cancer cases in China, accounting for 22.0% of all new cancer cases in China; there were 0.73 million lung cancer deaths in China, representing 28.5% of all cancer deaths in China. NSCLC is the predominant subtype, accounting for approximately 85% of all lung cancer cases. Among NSCLC patients, non-squamous NSCLC constituted approximately 65% of cases.

Immunotherapy (I-O), represented by anti-PD-1 monoclonal antibodies, has become a cornerstone treatment for various malignant tumors including lung cancer, breast cancer, liver cancer, esophageal cancer, and nasopharyngeal carcinoma, and covers nearly the entire treatment for cancer patients, encompassing adjuvant/neoadjuvant treatment for early-stage tumors, consolidation treatment after radical chemoradiation for locally advanced tumors, and first-line to last-line treatments for advanced tumors. Currently, most immunotherapy drugs in China are administered intravenously, and this not only requires lengthy infusion times but also imposes significant inconvenience on patients. There is an urgent clinical need to enhance the convenience of immunotherapy.

The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized controlled phase III clinical study led by the principal investigator Professor Wu Lin from Hunan Cancer Hospital* (湖南省腫瘤醫院), and is the first phase III clinical study of domestic anti-PD-1 monoclonal antibody subcutaneous formulation. The study aims to compare the exposure, efficacy and safety of JS001sc and toripalimab injection in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous NSCLC. The results have showed that the drug exposure of JS001sc was non-inferior to that of toripalimab injection with comparable efficacy and safety profiles. The detailed data of this study would be presented at a recent international academic conference. The Company plans to communicate with the regulatory authorities, and submit new drug application of JS001sc for all approved indications of TUOYI®.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above project and fulfill its information disclosure obligations in a timely manner for subsequent progress of the project in strict compliance with relevant regulations.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 24 November 2025

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purpose only*